Risk Stratification in Multiple Myeloma.

about

Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma.

P2860

Q37108574-E44587B2-07A0-44C1-9ED1-F2B89DC03DFA Q48153195-90D41B4B-E236-4270-97FA-51EEBCC8C421

P2860

Risk Stratification in Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q38736249

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Risk Stratification in Multiple Myeloma.

@en

type

Item

label

Risk Stratification in Multiple Myeloma.

@en

prefLabel

Risk Stratification in Multiple Myeloma.

@en

P1476

Risk Stratification in Multiple Myeloma.

@en

P2093

Melissa Gaik-Ming Ooi

http://www.w3.org/2001/XMLSchema#string

Sanjay de Mel

http://www.w3.org/2001/XMLSchema#string

Wee Joo Chng

http://www.w3.org/2001/XMLSchema#string

P2860

Appraisal of immunoglobulin free light chain as a marker of response

Prognostic significance of copy-number alterations in multiple myeloma

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Targeting the BRAF V600E mutation in multiple myeloma.

Frailty in older adults: evidence for a phenotype

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie

P2888

s11899-016-0307-4

P304

137-147

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0307-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1030889971

http://www.w3.org/2001/XMLSchema#string

P698

26883334

http://www.w3.org/2001/XMLSchema#string

Risk Stratification in Multiple Myeloma.

about

P2860

P2860

Risk Stratification in Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698